153 related articles for article (PubMed ID: 23135806)
1. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
[TBL] [Abstract][Full Text] [Related]
2. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
[TBL] [Abstract][Full Text] [Related]
3. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab infusion reactions: French pharmacovigilance database analysis.
Grandvuillemin A; Disson-Dautriche A; Miremont-Salamé G; Fourrier-Reglat A; Sgro C;
J Oncol Pharm Pract; 2013 Jun; 19(2):130-7. PubMed ID: 23154574
[TBL] [Abstract][Full Text] [Related]
5. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.
O'Neil BH; Allen R; Spigel DR; Stinchcombe TE; Moore DT; Berlin JD; Goldberg RM
J Clin Oncol; 2007 Aug; 25(24):3644-8. PubMed ID: 17704414
[TBL] [Abstract][Full Text] [Related]
6. [Incidence of infusion reactions induced by cetuximab chemotherapy].
Maeda T; Tatematsu M; Muro K
Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center.
Hansen NL; Chandiramani DV; Morse MA; Wei D; Hedrick NE; Hansen RA
J Oncol Pharm Pract; 2011 Jun; 17(2):125-30. PubMed ID: 20147576
[TBL] [Abstract][Full Text] [Related]
8. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab-associated infusion reactions: pathology and management.
Patel DD; Goldberg RM
Oncology (Williston Park); 2006 Oct; 20(11):1373-82; discussion 1382, 1392-4, 1397. PubMed ID: 17112000
[TBL] [Abstract][Full Text] [Related]
10. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
Muallaoglu S; Disel U; Mertsoylu H; Besen A; Karadeniz C; Taner Sumbul A; Abali H; Ozyilkan O
J BUON; 2013; 18(1):261-7. PubMed ID: 23613414
[TBL] [Abstract][Full Text] [Related]
11. Severe first infusion reaction related to cetuximab in cancer patients in Arkansas.
Atwal D; Safar AM; Govindarajan R; Makhoul I
J Oncol Pharm Pract; 2019 Jul; 25(5):1130-1134. PubMed ID: 29890919
[TBL] [Abstract][Full Text] [Related]
12. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
Chung CH
Oncologist; 2008 Jun; 13(6):725-32. PubMed ID: 18586928
[TBL] [Abstract][Full Text] [Related]
13. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
Shao YY; Hu FC; Liang JT; Chiu WT; Cheng AL; Yang CH
J Formos Med Assoc; 2010 May; 109(5):362-8. PubMed ID: 20497869
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Navo M; Kunthur A; Badell ML; Coffer LW; Markman M; Brown J; Smith JA
Gynecol Oncol; 2006 Nov; 103(2):608-13. PubMed ID: 16797060
[TBL] [Abstract][Full Text] [Related]
16. Management of severe infusion reactions after cetuximab.
Cerman J; Melichar B; Cermanova M; Solichova D
Acta Oncol; 2008; 47(8):1609-11. PubMed ID: 18607870
[No Abstract] [Full Text] [Related]
17. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.
Kang HJ; Park JS; Kim DW; Lee J; Jeong YJ; Choi SM; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
Respir Med; 2012 Mar; 106(3):443-50. PubMed ID: 22154502
[TBL] [Abstract][Full Text] [Related]
18. Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan.
Yamaguchi K; Watanabe T; Satoh T; Ishiguro M; Izawa M; Inoshiri S; Sugihara K; Sakata Y
Jpn J Clin Oncol; 2014 Jun; 44(6):541-6. PubMed ID: 24771864
[TBL] [Abstract][Full Text] [Related]
19. Low rate of cetuximab hypersensitivity reactions in Northeast Tennessee: An Appalachian effect?
Adams CB; Street DS; Crass M; Bossaer JB
J Oncol Pharm Pract; 2016 Dec; 22(6):784-789. PubMed ID: 26590031
[TBL] [Abstract][Full Text] [Related]
20. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors.
Lehmann DF; Hurteau TE; Newman N; Coyle TE
Clin Pharmacol Ther; 1997 Aug; 62(2):225-9. PubMed ID: 9284859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
